A Phase 3 interventional study of Ibrutinib and Gemcitabine in Metastatic Pancreatic Adenocarcinoma, sponsored by Pharmacyclics LLC.. Completed at 86 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-30.
Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a phase 3 study to evaluate the efficacy of ibrutinib in combination with nab-paclitaxel and gemcitabine for the first line treatment of patients with metastatic pancreatic adenocarcinoma.
Pharmacyclics LLC. is the lead sponsor of 54 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 9 (90%) have results posted.
First submitted before Pharmacyclics LLC. became part of AbbVie.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adequate hematologic function:
Adequate hepatic and renal function defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ibrutinib daily in combination with: Nab-paclitaxel and gemcitabine
Drug: Ibrutinib · Drug: Gemcitabine · Drug: Nab-paclitaxel
Placebo daily in combination with: Nab-paclitaxel and gemcitabine
Drug: Gemcitabine · Drug: Nab-paclitaxel
Also known as: IMBRUVICA®
Progression Free Survival (PFS)
PFS is defined as the time from the date of randomization until disease progression per RECIST 1.1 criteria assessed by investigator, or death from any cause, whichever occurs first.
Time frame: Results at an overall median follow-up of 24.87 months
Overall Survival (OS)
OS, is defined as the time from date of randomization until date of death from any cause.
Time frame: Results at an overall median follow-up of 24.87 months
Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib and Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine.
This is a measure of percentage of subjects with Treatment Emergent Adverse Events Grade 3 or above collected Up to 30 days after the last participating subject discontinues study drug.
Time frame: Results at an overall median follow-up of 24.87 months
Overall Response Rate
ORR is defined as the percentage of subjects who achieve a complete response or partial response, based on investigator assessment according to RECIST 1.1.
Time frame: Results at an overall median follow-up of 24.87 months
Clinical Benefit Response
Subject achieved a ≥50% reduction in pain intensity (Memorial Pain Assessment Card \[MPAC\]) or analgesic consumption, or a 20-point or greater improvement in KPS for a period of at least 4 consecutive weeks, without showing any sustained worsening in other parameters. OR Subject was stable on all of the aforementioned parameters, and showed a marked, sustained weight gain (≥7% increase maintained for ≥4 weeks) not due to fluid accumulation (Burris 1997).
Time frame: Results at an overall median follow-up of 24.87 months
Carbohydrate Antigen 19-9 (CA19-9) Response
The CA19-9 response rate is defined as the percentage of subjects with a decline of 20%, 90%, and other thresholds considered clinically meaningful, from baseline. This is a percentage of patients with \> or = 60% reduction from baseline.
Time frame: Results at an overall median follow-up of 24.87 months
Patient-reported Outcome (PRO) by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30).
Unit is the month: TUDD1 - the time between random \& 1st occurrence of a decrease in QLQ-C30 score ≥10 pts w/o improvement in QoL score of ≥10 points or any further QoL data due to deterioration. The proportion of subjects who met the "responder" criteria prior to subsequent anticancer therapy initiation. Response defined as achievement of a ≥50% reduction in MPAC visual analog scale which measures pain intensity or analgesic consumption, or a ≥20-point improvement from baseline in KPS sustained for a period of ≥ 4 consecutive weeks without showing any sustained worsening from baseline in any of the other parameters OR Subject stable on all parameters (pain and KPS), \& showed a marked, sustained weight gain (≥7% increase from baseline maintained for ≥4 weeks) not due to fluid accumulation.
Time frame: Results at an overall median follow-up of 24.87 months
Rate of Venous Thromboembolic Events (VTE)
The VTE rate is defined as percentage of subjects with Venous thromboembolic events (SMQ) per investigator assessment.
Time frame: Results at an overall median follow-up of 24.87 months
This study was conducted at 75 centers in the United States (US), European Union, and South Korea. The first subject enrolled 08 May 2015 and the last was enrolled on April 19, 2018.
| Milestone | Placebo+Gemcitabine+Nab-Paclitaxel | Ibrutinib+Gemcitabine+Nab-paclitaxel |
|---|---|---|
| Started | 213 | 211 |
| Completed | 212 | 207 |
| Not completed | 1 | 4 |
PFS is defined as the time from the date of randomization until disease progression per RECIST 1.1 criteria assessed by investigator, or death from any cause, whichever occurs first.
| Months | Ibrutinib+Gemcitabine+Nab-paclitaxel | Placebo+Gemcitabine+Nab-Paclitaxel |
|---|---|---|
| Progression Free Survival (PFS) | 5.32 (3.75 to 5.49) | 6.01 (5.45 to 7.16) |
OS, is defined as the time from date of randomization until date of death from any cause.
| Months | Ibrutinib+Gemcitabine+Nab-paclitaxel | Placebo+Gemcitabine+Nab-Paclitaxel |
|---|---|---|
| Overall Survival (OS) | 9.69 (8.57 to 10.41) | 10.78 (8.94 to 11.66) |
This is a measure of percentage of subjects with Treatment Emergent Adverse Events Grade 3 or above collected Up to 30 days after the last participating subject discontinues study drug.
| percentage of participants | Placebo+Gemcitabine+Nab-Paclitaxel | Ibrutinib+Gemcitabine+Nab-paclitaxel |
|---|---|---|
| Subjects with any TEAE >= Grade 3 | 86.8 | 85.6 |
| Subjects with ibrutinib/pbo-related TEAE >=Grade 3 | 55.7 | 54.3 |
ORR is defined as the percentage of subjects who achieve a complete response or partial response, based on investigator assessment according to RECIST 1.1.
| percentage of Patients | Placebo+Gemcitabine+Nab-Paclitaxel | Ibrutinib+Gemcitabine+Nab-paclitaxel |
|---|---|---|
| Overall Response Rate | 42.3 (35.5 to 49.2) | 29.5 (23.3 to 36) |
Subject achieved a ≥50% reduction in pain intensity (Memorial Pain Assessment Card \[MPAC\]) or analgesic consumption, or a 20-point or greater improvement in KPS for a period of at least 4 consecutive weeks, without showing any sustained worsening in other parameters. OR Subject was stable on all of the aforementioned parameters, and showed a marked, sustained weight gain (≥7% increase maintained for ≥4 weeks) not due to fluid accumulation (Burris 1997).
| percentage of patients | Placebo+Gemcitabine+Nab-Paclitaxel | Ibrutinib+Gemcitabine+Nab-paclitaxel |
|---|---|---|
| Achieved a >=50% reduction in pain intensity | 25.8 | 27.5 |
| >=20-pt improvement in KPS (>=4 consecutive weeks) | 1.4 | 0 |
| Sustained weight gain (>=7% maintained >4 weeks | 11.7 | 5.7 |
The CA19-9 response rate is defined as the percentage of subjects with a decline of 20%, 90%, and other thresholds considered clinically meaningful, from baseline. This is a percentage of patients with \> or = 60% reduction from baseline.
| percentage of patients | Placebo+Gemcitabine+Nab-Paclitaxel | Ibrutinib+Gemcitabine+Nab-paclitaxel |
|---|---|---|
| Carbohydrate Antigen 19-9 (CA19-9) Response | 62.9 (56.0 to 69.4) | 53.6 (46.6 to 60.4) |
Unit is the month: TUDD1 - the time between random \& 1st occurrence of a decrease in QLQ-C30 score ≥10 pts w/o improvement in QoL score of ≥10 points or any further QoL data due to deterioration. The proportion of subjects who met the "responder" criteria prior to subsequent anticancer therapy initiation. Response defined as achievement of a ≥50% reduction in MPAC visual analog scale which measures pain intensity or analgesic consumption, or a ≥20-point improvement from baseline in KPS sustained for a period of ≥ 4 consecutive weeks without showing any sustained worsening from baseline in any of the other parameters OR Subject stable on all parameters (pain and KPS), \& showed a marked, sustained weight gain (≥7% increase from baseline maintained for ≥4 weeks) not due to fluid accumulation.
| months | Placebo+Gemcitabine+Nab-Paclitaxel | Ibrutinib+Gemcitabine+Nab-paclitaxel |
|---|---|---|
| Patient-reported Outcome (PRO) by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30). | 6.14 (4.86 to 8.21) | 4.21 (2.86 to 5.82) |
The VTE rate is defined as percentage of subjects with Venous thromboembolic events (SMQ) per investigator assessment.
| Percentage of Participants | Placebo+Gemcitabine+Nab-Paclitaxel | Ibrutinib+Gemcitabine+Nab-paclitaxel |
|---|---|---|
| Rate of Venous Thromboembolic Events (VTE) | 10.8 (7.0 to 15.8) | 8.1 (4.8 to 12.6) |
Collected over From first dose of study drug up to 30 days after the last dose of study drug. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Plus Nab-paclitaxel and Gemcitabine) | 188/212 (88.7%) | 127/212 (59.9%) | 211/212 (99.5%) |
| Ibrutinib (Plus Nab-paclitaxel and Gemcitabine) | 189/208 (90.9%) | 112/208 (53.8%) | 208/208 (100%) |
| Event | Placebo (Plus Nab-paclitaxel and Gemcitabine) | Ibrutinib (Plus Nab-paclitaxel and Gemcitabine) |
|---|---|---|
| PyrexiaGeneral disorders | 17/212 | 13/208 |
| DiarrhoeaGastrointestinal disorders | 9/212 | 14/208 |
| PneumoniaInfections and infestations | 8/212 | 13/208 |
| Abdominal painGastrointestinal disorders | 11/212 | 4/208 |
| CholangitisHepatobiliary disorders | 4/212 | 9/208 |
| AnaemiaBlood and lymphatic system disorders | 9/212 | 7/208 |
| NauseaGastrointestinal disorders | 7/212 | 3/208 |
| AstheniaGeneral disorders | 7/212 | 6/208 |
| NeutropeniaBlood and lymphatic system disorders | 3/212 | 6/208 |
| Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 6/212 | 6/208 |
| Event | Placebo (Plus Nab-paclitaxel and Gemcitabine) | Ibrutinib (Plus Nab-paclitaxel and Gemcitabine) |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 109/212 | 147/208 |
| NauseaGastrointestinal disorders | 107/212 | 116/208 |
| AstheniaGeneral disorders | 93/212 | 100/208 |
| AnaemiaBlood and lymphatic system disorders | 95/212 | 90/208 |
| AlopeciaSkin and subcutaneous tissue disorders | 87/212 | 90/208 |
| VomitingGastrointestinal disorders | 86/212 | 85/208 |
| PyrexiaGeneral disorders | 82/212 | 85/208 |
| Decreased appetiteMetabolism and nutrition disorders | 76/212 | 85/208 |
| NeutropeniaBlood and lymphatic system disorders | 84/212 | 68/208 |
| FatigueGeneral disorders | 65/212 | 78/208 |
| Age, Categorical(Participants) | Pbo+n-P/G | Ibr+n-P/G | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 119 | 118 | 237 |
| >=65 years | 94 | 93 | 187 |
| Age, Continuous(Years) | Pbo+n-P/G | Ibr+n-P/G | Total |
|---|---|---|---|
| Median | 64.0 (32 to 85) | 64.0 (32 to 82) | 64.0 (32 to 85) |
| Sex: Female, Male(Participants) | Pbo+n-P/G | Ibr+n-P/G | Total |
|---|---|---|---|
| Female | 92 | 97 | 189 |
| Male | 121 | 114 | 235 |
| Ethnicity (NIH/OMB)(Participants) | Pbo+n-P/G | Ibr+n-P/G | Total |
|---|---|---|---|
| Hispanic or Latino | 11 | 7 | 18 |
| Not Hispanic or Latino | 197 | 198 | 395 |
| Unknown or Not Reported | 5 | 6 | 11 |
| Race (NIH/OMB)(Participants) | Pbo+n-P/G | Ibr+n-P/G | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 59 | 53 | 112 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 7 | 5 | 12 |
| White | 142 | 146 | 288 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 5 | 6 | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of May 2015, a primary completion of Oct 2018 and a completion of Apr 2019. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2020, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibrutinib